Molecular detection of genotypic clarithromycin‐resistant strains and its effect on the eradication rate of concomitant therapy in Helicobacter pylori infection

Khun Nyi Nyi,Aye Min Soe,Zaw Min Htut
DOI: https://doi.org/10.1002/ygh2.476
2021-07-19
GastroHep
Abstract:The antimicrobial eradication rates for H. pylori have been decreasing and the reason for treatment failure was found to be one or more of the antibiotics resistance of the H pylori infection. Clarithromycin resistance to H. pylori was associated with the point mutations in the 23S rRNA gene and PCR-RFLP method can detect these point mutations. The study was aimed to study the molecular detection of genotypic clarithromycin resistant strains and its effect on eradication rate of concomitant therapy in H. pylori infection. This hospital based cross sectional analytic study was conducted between October 2019 and October 2020 at No. (2) Military Hospital (500-bedded) and Defence Services Medical Academy, Yangon. The presence of H. pylori DNA confirmed by amplifying the UreC gene by polymerase chain reaction and point mutations on 23S rRNA (A2142G and A2143G) were detected by PCR-RFLP. Total 98 H pylori infected patients were involved and among them, genotypic clarithromycin sensitive strain was 93.9% and resistant strain was 6.1%. All patients were found to have A2143G point mutation but A2142G was not detected. Successful eradication rate of concomitant therapy was found to be 89.8% and unsuccessful rate was 10.2%. Among patients with clarithromycin resistant gene, only 16.7% had successful eradication and 83.3% had unsuccessful eradication. There was statistically significant association between failure rate of concomitant therapy and detection of clarithromycin resistant gene (p value < 0.01). Presence of A2143G point mutation of clarithromycin resistant strain has negative effect on eradication of H. pylori infection.
What problem does this paper attempt to address?